Table 1 Correlation between the clinicopathological factors and expression of miR-205-5p and ANGPT2 in endometriosis
From: miR-205-5p inhibits human endometriosis progression by targeting ANGPT2 in endometrial stromal cells
| miR-205-5p expression | ANGPT2 expression | |||||
|---|---|---|---|---|---|---|
| High | Low | P | High | Low | P | |
| Patients (n) | 19 | 49 | 45 | 23 | ||
| Age (years) | 31.26 ± 5.98 | 31.98 ± 6.36 | 0.67 | 32.18 ± 6.43 | 31.00 ± 5.85 | 0.464 |
| Haemoglobin (g/L) | 113.89 ± 15.08 | 114.80 ± 18.00 | 0.85 | 113.98 ± 18.07 | 115.65 ± 15.44 | 0.706 |
| Endometrial phase (%) | ||||||
| Proliferative phase | 78.95% | 83.67% | 82.22% | 82.61% | ||
| Secretive phase | 21.05% | 16.33% | 0.917 | 17.78% | 17.39% | 0.97 |
| Dysmenorrhoea pain score (%) | ||||||
| Less than 4 points | 57.89% | 30.61% | 28.89% | 56.52% | ||
| More than 4 points | 42.11% | 69.39% | 0.038 | 71.11% | 43.48% | < 0.001 |
| Chronic pelvic pain score (%) | ||||||
| Less than 4 points | 42.11% | 36.69% | 31.11% | 47.83% | ||
| More than 4 points | 57.89% | 65.31% | 0.57 | 68.89% | 52.17% | 0.18 |
| E2 (pmol/L) | 369.58 ± 355.63 | 296.55 ± 301.26 | 0.245 | 276.76 ± 279.00 | 395.61 ± 373.30 | 0.054 |
| CA-125 (kU/L) | 34.31 ± 21.27 | 109.55 ± 140.91 | 0.001 | 116.67 ± 144.86 | 33.47 ± 21.40 | < 0.001 |
| Endometriosis score (%) | ||||||
| Less than 16 points | 68.42% | 38.78% | 35.56% | 69.57% | ||
| More than 16 points | 31.58% | 61.22% | 0.028 | 64.44% | 30.43% | 0.008 |